(IN BRIEF) AstraZeneca and Eccogene have signed an exclusive license agreement for ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) designed for the treatment of obesity, type-2 diabetes, and other cardiometabolic conditions. Initial results from the Phase … Read the full press release
Posted in Business, Education, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Adrian Kemp, AstraZeneca, Cardiometabolic Conditions, ECC5004, Eccogene, Exclusive License, Jingye Zhou, Obesity, Oral GLP-1RA, partnership, Sharon Barr, sustainability, type 2 diabetes
(IN BRIEF) New research from the University of East Anglia has found that being vaccinated against Covid-19 can halve the risk of developing long Covid. The study, which is the largest of its kind and includes more than 860,000 patients, … Read the full press release
Posted in Education, Healthcare, Management, Media, News, Science, United Kingdom
Tagged anxiety, asthma, comorbidities, COPD, coronary heart disease, depression, Dr Eleana Ntatsaki, hospitalisation, immunosuppression, long Covid, overweight, Prof Vassilios Vassiliou, risk factors, smokers, study, type 2 diabetes, University of East Anglia, vaccinated, WOMEN
(PRESS RELEASE) PARIS, 12-Apr-2022 — /EuropaWire/ — Diabeloop, a pioneer in the field of therapeutic artificial intelligence, leverages the potential of its diabetes technology to enable the integration of insulin pens into its hybrid closed-loop system using a unique app. … Read the full press release
Posted in Denmark, France, Healthcare, News, Pharma & Biotech, Spain, Technology
Tagged aid, automated insulin delivery, BIOCORP, DBL-4pen, DBL-hu, DBLG1, Diabeloop, Diabetes, Erik Huneker, insulin pen, insulin therapy, Mallya®, Marc Julien, multiple daily insulin injections, Prof. Hélène Hanaire, Seagrove Partners, Simon-Kucher, smart pen, Stéphanie JEGU, therapeutic AI, type 1 diabetes, type 2 diabetes, University Hospital of Toulouse, YourLoops
Scientists are closer to understanding the genetic causes of type 2 diabetes by identifying 111 new chromosome locations (‘loci’) on the human genome that indicate susceptibility to the disease, according to a UCL-led study in collaboration with Imperial College London. … Read the full press release
Posted in Education, Healthcare, Science, United Kingdom
Tagged Dr Nikolas Maniatis, Dr Toby Andrew, genetic causes of type 2 diabetes, type 2 diabetes, UCL
NOTTINGHAM, 04-Oct-2016 — /EuropaWire/ — Failure to assess people’s language skills when recruiting patients to clinical trials for diabetes treatments may be leading to black, Asian and ethnic minority (BAME) patients being underrepresented or excluded, says a new study. BAME patients … Read the full press release
STOCKHOLM, 27-Sep-2016 — /EuropaWire/ — New understanding of how hormone-producing cells in the pancreas decode their genetic instructions is pointing to novel targets for next generation medicines for type 2 diabetes, obesity and other metabolic disorders. A large scale analysis of … Read the full press release
Leicestershire, UK, 20-Sep-2016 — /EuropaWire/ — A new drive to raise awareness of Type 2 diabetes in ethnic minority communities in Leicestershire has been launched. A six-month programme of activities, including dancing sessions and healthy eating workshops, has started in a … Read the full press release
LIVERPOOL, 12-11-2015 — /EuropaWire/ — Researchers from the University of Liverpool, working with colleagues from Oxford and international partners, have improved the understanding of the processes that can lead to the development of type 2 diabetes. The research, published in Nature Genetics, shows … Read the full press release
Posted in Education, Healthcare, Science, United Kingdom
Tagged DNA sequence, Nature Genetics, Professor Mark McCarthy, type 2 diabetes, University of Liverpool
LixiLan met primary endpoint showing superior reduction in HbA1c vs Insulin Glargine alone PARIS, 14-9-2015 — /EuropaWire/ — Sanofi announced today that the LixiLan-L Phase III clinical trial met its primary endpoint in patients with type 2 diabetes treated with insulin glargine with … Read the full press release
Posted in France, Healthcare, Pharma & Biotech, Science
Tagged glargine, insulin, LixiLan-L Phase III clinical trial, metformi, Sanofi, type 2 diabetes
Ingelheim, Germany and Indianapolis, US, 24-8-2015 — /EuropaWire/ — Boehringer Ingelheim and Eli Lilly and Company today announced positive top-line results from EMPA-REG OUTCOME®. This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance® (empagliflozin) in more than 7,000 … Read the full press release
Initial combinations of empagliflozin and metformin in patients with T2D led to significant reductions in blood glucose vs. empagliflozin or metformin alone at 24 weeks Ingelheim, Germany and Indianapolis, US, 8-6-2015 — /EuropaWire/ — A Phase III clinical trial has … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Science
Tagged blood glucose, Boehringer Ingelheim, empagliflozin, metformin, Professor Hans-J. Woerle, type 2 diabetes
People with type 2 diabetes are physically less able to recover from stress, finds a study by scientists at UCL and the University of Zurich, funded by the British Heart Foundation. LONDON, 22-10-2014 — /EuropaWire/ — These findings could lead … Read the full press release
Posted in Education, Healthcare, United Kingdom
Tagged Dr Sanjay Thakrar, Professor Andrew Steptoe, stress, the University of Zurich, type 2 diabetes, UCL
London, UK, 15-1-2014 — /EuropaWire/ — AstraZeneca and Bristol-Myers Squibb Company announced the US Food and Drug Administration (FDA) approved FARXIGA™ [far-SEE-ga] (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycaemic control in adults with … Read the full press release
2-7-2013 — /europawire.eu/ — New Phase III data presented at the American Diabetes Association 73rd Scientific Sessions® (ADA) showed linagliptin improved blood glucose control as monotherapy and in combination with metformin, in Asian people from China, Malaysia and the Philippines with … Read the full press release
Ingelheim, Germany and Indianapolis, US, 1-7-2013 — /europawire.eu/ — Boehringer Ingelheim and Eli Lilly and Company today announced results from a new analysis of Phase III data demonstrating that treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is not associated with … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech, Science
Tagged 73rd Scientific Sessions®, American Diabetes Association, Boehringer Ingelheim, Diabetes, dipeptidyl peptidase-4, DPP-4, Dr. Odd Erik Johansen, Eli Lilly, Germany, Indianapolis, Ingelheim, Linagliptin, T2D, type 2 diabetes, US
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
